Navigation Links
Par Pharmaceutical Companies Reports Third Quarter 2011 Results
Date:11/2/2011

p>

9,61010,14528,39737,457Selling, general and administrative

35,76250,302128,863140,402Settlements and loss contingencies, net

-2,312190,560(1,694)Restructuring costs

--26,986-Total operating expenses

45,37262,759374,806176,165Gain on sale of product rights and other

-79-6,000Operating income (loss)

39,73240,614(81,023)108,098Gain on marketable securities and other
investments, net

-3,567-3,567Interest income

160341965942Interest expense

(150)(928)(451)(2,754)Income (loss) from continuing operations before
provision for income taxes

39,74243,594(80,509)109,853Provision (benefit) for income taxes

17,68712,933(2,900)34,731Income (loss) from continuing operations

22,05530,661(77,609)75,122Discontinued operations:Provision (benefit) for income taxes

127127380(105)(Loss) income from discontinued operations

(127)(127)(380)105Net income (loss)

$21,928$30,534($77,989)$75,227Basic earnings (loss) per share of common stock:Income (loss) from continuing operations

$0.61$0.89($2.16)$2.20(Loss) income from discontinued operations

(0.00)(0.00)(0.01)0.00Net income (loss)  

$0.61$0.89($2.17)$2.20Diluted earnings (loss) per share of common stock:Income (loss) from continuing operations

$0.60$0.86($2.16)$2.12(Loss) income from discontinued operations

(0.00)(0.00)(0.01)0.00Net income (loss)  

$0.60$0.86($2.17)$2.12Weighted average number of common shares
outstanding:  Basic

36,14334,31035,87534,117  Diluted

36,77435,68435,87535,410Reconciliation Between Reported (GAAP); Adjusted Income (Loss) from Continuing Operations and "Cash EPS"(In Thousands, Except Per Share Data)(Unaudited)Three Months EndedSeptember 30,September 30,20112010Income from Continuing Operations$22,055$30,661Transaction costs for Edict and Anchen

2,852-Upfront and development milestone payments

-2,000Litigation
'/>"/>

SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)...  The National Association of Drug Diversion Investigators ... the real-time, pseudoephedrine (PSE) blocking system in Indiana. The ... (NPLEx), automatically blocks unlawful PSE sales and helps ... make arrests. Data released by NPLEx shows electronic ... the sale of more than 32,105 boxes of medicine ...
(Date:8/20/2014)...  The National Association of Drug Diversion Investigators ... the real-time, pseudoephedrine (PSE) blocking system in Missouri. The ... (NPLEx), automatically blocks unlawful pseudoephedrine sales and helps ... make arrests. Data released by NPLEx shows electronic ... the sale of more than 19,030 boxes of medicine ...
(Date:8/20/2014)... NEW YORK , Aug. 20, ... a new market research report is ... The Market for Hospital-Acquired Infection Control ... http://www.reportlinker.com/p01618925/The-Market-for-Hospital-Acquired-Infection-Control-Sterilization-Disinfection-Testing-and-Treatment.html ... and healthcare-associated infections (HAIs), demand has ...
Breaking Medicine Technology:Indiana's Stop-Sale System Achieves Significant Results In Battle Against Meth 2Missouri's Stop-Sale System Achieves Significant Results In Battle Against Meth 2The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 2The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 3The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 4The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 5The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 6
... on Advances in ... Cancer in Women, SEATTLE, Sept. 14 Cell Therapeutics, ... Health,Research, the Lung Cancer Alliance and others, will support a ... Hill to discuss advances in the research and treatment of ...
... Study results outline dabigatran etexilate as potential thromboprophylaxis ... total hip replacement surgery, RIDGEFIELD, Conn., Sept. ... 15 issue of The Lancet will publish results,from ... a,potential therapy for patients undergoing total hip replacement ...
Cached Medicine Technology:Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill 2Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill 3The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor 2The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor 3
(Date:8/21/2014)... August 22, 2014 DoudouneCanadienneGoosePasCher.fr, one of ... products, has recently unveiled its new selection of Trillium ... has announced that all these fashionable and comfortable items ... The special offer will last until September 01. ... announce the new Canada Goose Trillium Parkas ...
(Date:8/21/2014)... BambooIndustry.com is an internationally well-known supplier and ... unveiled its new collection of elegant bamboo floorings ... who are looking for high quality floorings for their ... great savings (up to 29 percent off). Before the ... products. , The company’s bamboo flooring products are ...
(Date:8/21/2014)... Using heart-lung support technology, the University of Michigan,s Transplant ... livers and pancreases available for transplant by about 20 ... Transplantation and detail the impact of more ... ECMO, to improve the quality and viability of organs ... is limited by the number of donated organs available, ...
(Date:8/21/2014)... Improv performers from Fun House Theatre ... at Silverado Turtle Creek memory care community in Dallas. ... ranging from ages 10 to 16, delivers a groundbreaking ... set. The troupe's philosophy is that improv is based ... to touch audiences regardless of their circumstance — including ...
(Date:8/21/2014)... -- Black mothers are less likely than white moms ... why: Hospitals in neighborhoods with many black residents do ... more white residents, a U.S. government study finds. ... in medical centers where the black population is higher ... Control and Prevention reported Thursday. These practices include ...
Breaking Medicine News(10 mins):Health News:Fashionable And Comfortable Canada Goose Trillium Parkas For Sale At DoudouneCanadienneGoosePasCher.fr 2Health News:Buy Elegant Bamboo Floorings from Internationally Well-known Supplier BambooIndustry.com 2Health News:Extracorporeal support can significantly increase number of organs for transplant 2Health News:Unicorn Clearance Improv Troupe Brings Laughter to Residents with Dementia at Silverado Memory Care 2Health News:Racial Disparities in Breast-Feeding May Start With Hospitals, Study Suggests 2
... Hillenbrand,Industries, Inc. (NYSE: HB ) (the "Company") ... cash tender offer to purchase,any and all of its ... of which $250 million in aggregate principal amount was,outstanding ... being made,pursuant to an Offer to Purchase dated February ...
... TSX: COM, VANCOUVER, March 17 /PRNewswire-FirstCall/ ... announced positive interim clinical results,from its 90-day ... interim analysis,demonstrated statistically significant efficacy for the ... as compared to placebo. The,safety data from ...
... March 17 Researchers will unveil a,new ... been shown in numerous,published studies to help ... the performance of daily living tasks essential ... Corporation, a San,Francisco-based neuroscience company, will introduce ...
... currently undergoing human trials in Europe for treating Hepatitis ... damage in Duchenne and other forms of muscular dystrophy ... Medical Center reported their results using three different mouse ... 16 by the journal Nature Medicine. , The investigational ...
... enough slumber can contribute to weight gain, experts say, , , ... weight loss for some people be as simple as getting ... people who don,t get enough sleep tend to weigh more ... hormones leptin and ghrelin. , "There is a dynamic ...
... Team finalizes choice of mountain and route for June ... Hutchinson Cancer,Research Center,s Big Expedition for Cancer Research got ... this summer. The group returned today from,a photo flyover ... unclimbed,mountain in Alaska,s Glacier Bay National Park. The Big ...
Cached Medicine News:Health News:Hillenbrand Industries, Inc. Announces Early Tender Results of its Pending 'Any and All' Cash Tender Offer for its 4.50 Percent Senior Notes Due 2009 2Health News:Hillenbrand Industries, Inc. Announces Early Tender Results of its Pending 'Any and All' Cash Tender Offer for its 4.50 Percent Senior Notes Due 2009 3Health News:Hillenbrand Industries, Inc. Announces Early Tender Results of its Pending 'Any and All' Cash Tender Offer for its 4.50 Percent Senior Notes Due 2009 4Health News:Hillenbrand Industries, Inc. Announces Early Tender Results of its Pending 'Any and All' Cash Tender Offer for its 4.50 Percent Senior Notes Due 2009 5Health News:Cardiome Announces Positive Interim Phase 2b Results for Oral Vernakalant and Engages Merrill Lynch as Strategic Advisor 2Health News:Cardiome Announces Positive Interim Phase 2b Results for Oral Vernakalant and Engages Merrill Lynch as Strategic Advisor 3Health News:Cardiome Announces Positive Interim Phase 2b Results for Oral Vernakalant and Engages Merrill Lynch as Strategic Advisor 4Health News:Cardiome Announces Positive Interim Phase 2b Results for Oral Vernakalant and Engages Merrill Lynch as Strategic Advisor 5Health News:Cardiome Announces Positive Interim Phase 2b Results for Oral Vernakalant and Engages Merrill Lynch as Strategic Advisor 6Health News:New Brain Fitness Training Promotes Health and Independence of Long Term Care Insurance Policyholders 2Health News:New Brain Fitness Training Promotes Health and Independence of Long Term Care Insurance Policyholders 3Health News:Investigational drug tested for preventing muscle fiber death in muscular dystrophy 2Health News:Investigational drug tested for preventing muscle fiber death in muscular dystrophy 3Health News:Starved for Sleep? Watch Your Waistline 2Health News:Starved for Sleep? Watch Your Waistline 3Health News:Fred Hutchinson Cancer Research Center's Big Expedition for Cancer Research Team Returns From Reconnaissance Flight Over Alaska's Glacier Bay Park 2Health News:Fred Hutchinson Cancer Research Center's Big Expedition for Cancer Research Team Returns From Reconnaissance Flight Over Alaska's Glacier Bay Park 3
Each handle is designed to fit a specific trephine size....
Each handle is designed to fit a specific trephine size....
20 GA TITANIUM RETINAL FORCEPS...
... of German Craftsmanship have ... instrumentation in the world. ... available to you! Only ... Meisterbrief certificate, which requires ...
Medicine Products: